Condition
Nocturnal Bruxism
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 3 (1)
Trial Status
Unknown2
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06259786CompletedPrimary
Investigation of Adolescents With Nocturnal Bruxism
NCT05620316Not ApplicableCompletedPrimary
The Use of Low-Dose Botulinum Toxin Injection Into the Masseter Muscle to Treat Sleep Bruxism
NCT03827122Phase 2UnknownPrimary
Botulinum Toxin A Injectable Solution in the Management of Bruxism: A Clinical Trial Study
NCT02870543Phase 3UnknownPrimary
Efficacy of Phytolacca Decandra and Melissa Officinalis in Children With Nocturnal Bruxism
Showing all 4 trials